Cyclophosphamide (CP) is an important anticancer drug which belongs to the class of
alkylating agent. Cyclophosphamide is mostly used in bone marrow transplantation …

The care for patients with cancer has advanced greatly over the past decades. A
combination of earlier cancer diagnosis and greater use of traditional and new systemic …

Since the late 1990s, there has been a steady decline in cancer-related mortality, in part
related to the introduction of so-called targeted therapies. Intended to interfere with a specific …

Cardiac dysfunction resulting from exposure to cancer therapeutics was first recognized in
the 1960s, with the widespread introduction of anthracyclines into the oncological …

In the United States alone, there are currently approximately 14.5 million cancer survivors,
and this number is expected to increase to 20 million by 2020. Cancer therapies can cause …

Cardiotoxicity of anticancer treatments has become an increasingly important clinical
problem faced by cardiologists. Left ventricular systolic dysfunction and heart failure …

Chemotherapy, radiotherapy, targeted therapy, and immunotherapy have brought hope to
cancer patients. With the prolongation of survival of cancer patients and increased clinical …

Cyclophosphamide is increasingly used to treat various types of cancers and autoimmune
conditions. Higher doses of this drug may produce significant cardiac toxicity, including fatal …

Cardiovascular toxicity is a major challenge for the pharmaceutical industry and predictive
screening models to identify and eliminate pharmaceuticals with the potential to cause …

Although outcomes in cancer patients have dramatically improved with the development of
novel cancer chemotherapies and combination treatment, these developments are …